Friday, May 20, 2022 8:02:11 AM
RDEB is a rare genetic disorder caused by mutations in the gene encoding collagen type VII (C7) and is one of the most severe forms of epidermolysis bullosa, characterized by severe and painful skin blistering, as well as extreme fragility and scarring of mucous membranes throughout the body. There is currently no known cure or effective treatment available for patients suffering from this disease.
"In patients with recessive dystrophic epidermolysis bullosa (RDEB) even minor friction or trauma can cause debilitating blistering, tearing and scarring of the skin, along with severe pain and itching. Our data shows that treatment with PTR-01 led to rapid, consistent, and durable wound healing," said Sanuj K. Ravindran, M.D., executive chairman of Phoenix Tissue Repair. "We are hopeful that by addressing the root cause of this rare disease, we will be able to provide a treatment beyond daily wound care and pain management for patients in need."
History.htm
Recent BBIO News
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/17/2024 10:41:54 PM
- BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA • GlobeNewswire Inc. • 09/17/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 09:04:54 PM
- BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program • GlobeNewswire Inc. • 09/10/2024 08:45:00 PM
- BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) • GlobeNewswire Inc. • 09/10/2024 08:45:00 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/06/2024 11:30:00 AM
- BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension • GlobeNewswire Inc. • 08/30/2024 02:50:00 PM
- BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 • GlobeNewswire Inc. • 08/29/2024 11:30:00 AM
- BridgeBio Pharma to Participate in September Investor Events • GlobeNewswire Inc. • 08/28/2024 11:30:00 AM
- BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence • GlobeNewswire Inc. • 08/26/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:27:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:24:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 08:29:34 PM
- BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia • GlobeNewswire Inc. • 08/19/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:39:33 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/08/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/01/2024 09:06:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:24:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:31:13 AM
- BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 12:16:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:12:59 PM
- BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer • GlobeNewswire Inc. • 07/23/2024 11:30:00 AM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/05/2024 08:31:00 PM
- BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) • GlobeNewswire Inc. • 06/18/2024 11:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM